Aortic root dissection is the main cause of mortality in Marfan syndrome. Recent studies suggest that losartan could more effective to slow aortic root enlargement than beta blockers.
Primary end point was rate of aortic root enlargement expressed as the change in maximum diameter indexed to body surface area at 3 years.
Between 2007 and 2011, 608 patients between 6 months and 25 years of age (median age 11.2 ± 6.3 years) were included. There were no baseline clinical or echocardiography differences in the two groups.
In both groups, showed a reduced rate of aortic enlargement though there were no significant differences between both treatments.
Conclusion
In children and Young adults with Marfan syndrome, no significant differences were observed regarding aortic root enlargement between patients receiving atenolol or losartan.
Ronald V. Lacro
2014-11-19
Original title: Randomized Trial of Atenolol Versus Losartan in Children and Young Adults With Marfan Syndrome.
